Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib + Sunitinib in Metastatic Renal Cell Carcinoma
NCT00853372Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2009
- Primary completion
- Aug 2011
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of trebananib in renal cell carcinoma (RCC), sponsored by Amgen. Started May 2009; status: completed.
02
Drugs
trebananib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00853372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853372.